August 21, 2024 07:12 AM EDT
Deals
R&D

Dr. Red­dy's and Stan­ford spin­out Kain­o­myx part­ner up on an­ti-malar­i­al pro­gram

Katherine Lewin

News Reporter

Dr. Red­dy’s Lab­o­ra­to­ries, its CRD­MO arm Au­ri­gene and Stan­ford spin­out Kain­o­myx are team­ing up to de­vel­op an an­ti-malar­i­al drug with a new mech­a­nism of ac­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Mod­er­na plans $1.1B in R&D and pro­gram cuts, de­lays break-even point to 2028

Sanofi buys in­to ra­dio­phar­ma­ceu­ti­cal field with $110M up­front, go­ing af­ter space held by No­var­tis

A new start­up wants to fight can­cer with 'off-the-shelf' gene ther­a­py, se­cur­ing $26M seed round

Sofinno­va’s Jim Healy on ‘more ra­tio­nal mar­ket’ as four biotech star­tups near their IPOs

J&J ex­pands Trem­fya in­to IBD with new FDA ap­proval

Au­ra's in­frared light-ac­ti­vat­ed drug stops tu­mor growth and pre­serves vi­sion in eight eye can­cer pa­tients

A service from the Financial Times